Correction: Activation of RAS/MAPK pathway confers MCL-1 mediated acquired resistance to BCL-2 inhibitor venetoclax in acute myeloid leukemia

Affiliations

• ¹ Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
• ² AbbVie Inc., North Chicago, IL, USA.
• ³ Institute of Hematology, Chinese Academy of Medical Sciences & Peking Union Medical College, Tianjin, China.
• ⁴ Department of Nutritional Sciences, Department of Pediatrics, Department of Oncology, Dell Medical School, The University of Texas at Austin, Austin, TX, 78712, USA.
• ⁵ Department of Cell, Developmental & Cancer Biology, Division of Hematology & Medical Oncology, Knight Cancer Institute, Oregon Health & Science University, Portland, OR, USA.
• ⁶ Université de Paris, Institut de la Recherche Saint-Louis (IRSL), Inserm Unit 1131, Paris, France.
• ⁷ Dana-Farber Cancer Institute, Boston, MA, USA.
• ⁸ Department of Hematopathology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
• ⁹ Princess Margaret Cancer Center, Toronto, ON, Canada.
• ¹⁰ High Resolution Electron Microscopy Facility, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
• ¹¹ Department of Bioinformatics & Computational Biology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
• ¹² Department of Hematology, The First Hospital Affiliated Harbin Medical University, Harbin, China.
• ¹³ Department of Lymphoma & Myeloma Research, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
• ¹⁴ Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, TX, USA. mkonople@mdanderson.org.